Nasdaq Grants Listing Extension
![](https://tracker.live.rns-distribution.com/track.live-rns/5323747_d9353a075fe0b610698e373da828b7e4.png)
("Renalytix" or the "Company")
Nasdaq Grants Listing Extension
Renalytix's American Depositary Shares ("ADSs") will continue trading on the Nasdaq Capital Market effective at the open of trading on
As previously announced on
The Panel considered all information provided and granted the Company's request for an exception through
As a reminder, the Company confirms that it is in advanced discussions with key stakeholders of the business, who have indicated their support for management to achieve the Company's goals of the refreshed business plan, with focused expenditure and investment alongside reduced operating costs, and a suitable capital structure and funding. The Company will continue to assess options to maximise value for its shareholders and further updates will be made as appropriate.
Having achieved significant milestones for the business, including FDA approval for KidneyIntelX, and a final Medicare coverage determination for the Company's kidneyintelX.dkd testing with an established price of
Subsequent to the financings that were successfully completed earlier in 2024, the Company has cash runway extending into calendar Q4 2024, with an unaudited cash position of
This announcement contains inside information under the
For further information, please contact:
|
|
|
Via Walbrook PR |
|
|
Stifel (Nominated Adviser and Joint Broker) |
Tel: 020 7710 7600 |
|
|
|
|
|
Tel: 020 3179 5300 |
|
|
|
Tel: 020 7597 4000 |
|
|
|
|
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|
Mob: 07980 541 893 / 07407 804 654 / 07884 664 686 |
|
|
|
|
|
Tel: 415-389-6400 or investors@renalytix.com |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the